TSHA

Taysha Gene Therapies Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↓ 4/10
  • Value↓ 0/10
Taysha Gene Therapies sales and earnings growth
TSHA Growth
Neutral
  • Revenue Y/Y↓ 3.42%
  • EPS Y/Y↓ -11.76%
  • FCF Y/Y↓ -33.63%
Taysha Gene Therapies gross and profit margin trends
TSHA Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -1738.40%
  • ROIC 5Y↓ -778.81%
Taysha Gene Therapies net debt vs free cash flow
TSHA Risk
Great
  • Debt / Equity↓ 0.3
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -2449.5

Taysha Gene Therapies stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks